Polish Regulatory Authority Issues Positive Opinion For CNS Pharma's Brain Cancer Candidate

  • CNS Pharmaceuticals Inc's (NASDAQ: CNSP) partner WPD Pharmaceuticals received a favorable opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland, for its planned upcoming Berubicin trial in adults with Glioblastoma Multiforme (GBM) under the WPD-201 Clinical Trial Protocol.
  • CNS has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.
  • WPD plans to initiate both Berubicin Phase 2 adult GBM trial in the first half of 2021 and a pediatric malignant glioma Phase 1 clinical trial in 2021. Around 60% of the program budget is expected to be funded by the reimbursement grant.
  • In December last year, the FDA signed off CNS Pharma's IND for Berubicin. Phase 2 will start in the first quarter of 2021 to evaluate the efficacy and safety of Berubicin in the treatment of adults with GBM who have failed first-line therapy. 
  • Berubicin is the Company's novel anthracycline candidate for the treatment of many serious oncology indications, currently in development to treat GBM. CNS entered into a sublicense agreement with WPD in November 2019, which provided WPD the commercial rights in select territories in Europe and Asia to Berubicin.
  • Price Action: CNSP is down 3.06% at $3.17 in market trading hours on last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksGeneralbrain cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!